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ABSTRACT 
Aluminum has no known biological function; however, it is a contaminant present in most 
foods and medications. Aluminum is excreted by the renal system, and patients with renal 
diseases should avoid aluminum-containing medications. Studies demonstrating long-
term toxicity from the aluminum content in parenteral nutrition components led the US 
Food and Drug Administration to implement rules for these solutions. Large-volume 
ingredients were required to reduce the aluminum concentration, and small-volume 
components were required to be labeled with the aluminum concentration. Despite these 
rules, the total aluminum concentration from some components continues to be above 
the recommended final concentration. The concerns about toxicity from the aluminum 
present in infant formulas and antiperspirants have not been substantiated but require 
more research. Aluminum is one of the most effective adjuvants used in vaccines, and a 
large number of studies have documented minimal adverse effects from this use. Long-
term, high-concentration exposure to aluminum has been linked in meta-analyses with 
the development of Alzheimer disease. 
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INTRODUCTION 
Aluminum is one of the most common metals on earth.1 Aluminum is lightweight, strong, 
and easily sterilizable; therefore, it is used in a variety of packaging and manufacturing 
processes, such as milling and blending. These uses result in the presence of aluminum 
in our food, water supply, and medications. The aluminum present in the body normally 
enters via gastrointestinal ingestion. However, the gastrointestinal mucosa is 
exceptionally efficient in preventing absorption, and little to none of ingested aluminum 
appears to be absorbed.1 One calculated fraction of aluminum absorption in adults was 
only 0.14%.1 Data from an adult human study in which an aluminum isotope was used 
revealed the absorption to be 0.08%.1 The Agency for Toxic Substances and Disease 
Registry of the US Department of Health and Human Services has set the minimum risk 
level for oral aluminum intake at 1 mg/kg per day.2 
The aluminum that does make it to the bloodstream is more than 80% bound to 
transferrin.3,4 The small amounts that are absorbed are quickly excreted. Tracer studies 
with radioactive aluminum in human adults have revealed that only 0.5% of the total 
aluminum concentration is still in the bloodstream 24 hours after injection.5,6 The great 
majority of aluminum that is in the bloodstream is cleared by the renal system.1 In contrast 
to the wide variety of minerals that have been found to have a role in an enzymatic 
metalloproteins, only aluminum has not been found to have any biological role. In fact, in 
the presence of renal disease, when normal barriers are bypassed, aluminum has been 
shown to have some clearly associated toxicity. 
Studies have revealed no biomarkers for aluminum levels in humans.2 Because 
aluminum is poorly absorbed and rapidly excreted by the renal system, concentrations 
measured in blood or urine do not reflect exposures unless they are acute excessive 
amounts. A study in which researchers compared serum, plasma, and 24-hour urine 
aluminum concentrations among different reference laboratory tests revealed wide 
variations in the reported numbers.7 The ranges used in these laboratory tests as normal 
were derived from small samples of normal individuals, often adults, and none that were 
age specific. The use of other tissues, such as hair, was found to be unreliable.7 
RENAL DISEASES 
 
 
The previous American Academy of Pediatrics policy statement on aluminum toxicity was 
focused on the aluminum effects observed in patients with renal disease.8 At that time, 
the dialysates used for peritoneal dialysis had a high aluminum level and bypassed the 
normal protective epithelial barriers. Because the patients had decreased renal function, 
they could not excrete the aluminum. These patients developed symptoms of bone pain. 
Adults on long-term aluminum-containing dialysate had increased aluminum 
concentrations in the brain, with progressive dementia.9 When the aluminum was 
removed from the dialysate, these issues resolved. Of ongoing concern was the use of 
aluminum-containing phosphate binders in pediatric patients with renal disease. Multiple 
case reports were published of patients who developed encephalopathy and had 
aluminum bone deposition.8 The previous policy recommended discontinuing the use of 
aluminum-containing phosphate binders in patients with renal disease. Awareness 
regarding aluminum toxicity resulted in discontinued use of these agents. Patients with 
renal disease should also avoid aluminum-containing antacids and medications, such 
sucralfate. 
PARENTERAL NUTRITION 
Intravenous compounds containing high aluminum concentrations have a risk of resulting 
in aluminum toxicity because they bypass the protective gastrointestinal mucosa. As 
indicated previously, aluminum is normally cleared quickly by the renal system. There is 
greater concern with high levels of aluminum intake over longer periods of time. 
Parenteral nutrition solutions are the most chronic intravenous infusions used in patient 
care. Aluminum is present in all of the ingredients of parenteral nutrition, the highest levels 
being found in calcium gluconate, inorganic phosphates, and cysteine hydrochloride.10 
DEVELOPMENTAL EFFECTS 
The blood-brain barrier is efficient at blocking the passage of aluminum into the brain3,11; 
however, this barrier may not be as well developed in preterm infants. Because preterm 
infants are known to have immature renal function, Bishop et al12 were concerned about 
aluminum toxicity in preterm infants receiving parenteral nutrition. They performed a study 
to compare 90 preterm infants randomly assigned to receive standard parenteral nutrition 
with 92 preterm infants randomly assigned to receive purposefully aluminum-depleted 
 
 
parenteral nutrition.12 At a postterm age of 18 months, a subgroup of the infants had the 
Bayley Scales of Infant Development Mental Developmental Index performed. The index 
score for 39 infants who received the standard aluminum-containing parenteral nutrition 
was 92, compared with a score of 102 for the 41 infants who received the aluminum-
depleted parenteral nutrition (P = .02). The study revealed a loss of 1 index point for each 
day infants received the standard aluminum-containing parenteral nutrition solution.12 
BONE EFFECTS 
As indicated earlier, there is little accumulation of aluminum in the body. The skeleton is 
the only part of the body that appears to concentrate aluminum, with 54% of the body’s 
total aluminum concentrated in bone.13 When aluminum accumulates to a high enough 
level, bone formation is blocked and osteomalacia develops, increasing the risk of 
fracture.1 An older study in which the authors evaluated preterm infants receiving 
parenteral nutrition revealed that aluminum deposited at the leading edge of bone 
mineralization.14 The same infants studied by Bishop et al12 were later examined for 
long-term bone effects. The researchers followed-up with these patients when they were 
13 to 15 years of age with dual-energy radiograph absorptiometry scans for bone mineral 
content. Patients who had received the standard (higher) aluminum parenteral nutrition 
were found to have lower lumbar spine bone mineral content, and patients with the 
highest intakes had lower bone mineral content of their hips.15 
REGULATORY RESPONSE 
In response to the studies cited here, the US Food and Drug Administration (FDA) 
became concerned about the aluminum content of intravenous solutions. In 1990, the 
FDA announced an intention to regulate the aluminum in parenteral solutions. In 2000, 
the final rule was published but did not take effect until July 26, 2004.16 The rule requires 
the reduction of aluminum content in large-volume parenteral nutrition solutions to less 
than 25 µg/L and requires that small-volume parenteral nutrition solutions be labeled to 
indicate the maximum aluminum concentration present on their expiration date. The 
expiration date is important because the aluminum level increases with time as it leaches 
out of the glass in the containers. One of the key requirements of the FDA was to add a 
warning onto the label stating that in patients with impaired renal function, infusion of 
 
 
solutions with more than 5 µg/kg per day of aluminum may result in central nervous 
system and bone toxicity.16 Because the labels on the components list the maximum 
aluminum concentration that could be present, when the actual final aluminum 
concentration of parenteral nutrition solutions has been measured, it has been less than 
the projected maximum value.17 Despite the solutions having lower aluminum 
concentrations than the component labels project, when actually measured, none of the 
compounded neonatal or pediatric parenteral nutrition solutions had an aluminum 
concentration below the FDA-recommended 5 µg/kg per day.17,18 When another group 
used the actual measured aluminum concentration in the components and formulated a 
parenteral nutrition solution with the lowest levels possible, the daily dose of aluminum 
was still greater than the recommended 5 µg/kg per day.19 When plasma aluminum 
concentrations were measured in patients with intestinal failure who were receiving long-
term parenteral nutrition, the average concentration was 8 times greater than that in 
healthy controls.20 The aluminum concentrations present in small-volume parenteral 
nutrition solutions have not changed since the studies that revealed a developmental 
effect were published. Unfortunately, until new parenteral components with lower 
aluminum content are available, no matter how thoughtful the prescriber, parenteral 
nutrition solutions for most pediatric patients will contain aluminum concentrations above 
the recommended amount. 
FORMULAS 
Studies have documented significantly higher aluminum concentrations in infant formulas 
compared with human milk.21,22 Despite this, there are no studies reporting any 
evidence of clinical aluminum toxicity related to formula feeding. Nonetheless, the 
disparity in the measured concentrations has resulted in some calls for an effort to reduce 
the aluminum content in infant formulas.22 As indicated earlier, there is minimal 
absorption of aluminum via the gastrointestinal tract, so regulatory agencies have not 
responded to these calls. One study measured the plasma aluminum concentrations of 
infants fed human milk versus a variety of infant formulas and found no significant 
differences, except with hydrolysate formulas.23 In this study, the hydrolysate formulas 
were all used in infants with a gastrointestinal illness; however, data on aluminum content 
 
 
in hydrolysate infant formulas are insufficient to make recommendations at this time. 
Studies are greatly needed on the potential health risks attributable to the aluminum in 
infant formulas, especially in populations such as preterm infants and those with 
gastrointestinal or renal diseases. 
ANTIPERSPIRANTS 
Skin is an excellent barrier against aluminum; however, claims have been made that the 
high levels of aluminum in antiperspirants lead to dermal absorption. This concern has 
been used to market antiperspirants low in aluminum. There are no published medical 
studies in which authors report large numbers of patients with toxicity attributable to 
transdermal aluminum absorption. The concern is that increased absorption may occur 
in skin that has been abraded by shaving. There is a single case report of an adult female 
patient who used a daily aluminum-containing antiperspirant, regularly shaved the skin 
under her arms, and had elevated aluminum concentrations.24 In vitro studies in which 
researchers used skin biopsies in a diffusion cell revealed little absorption of an aluminum 
antiperspirant preparation.25 However, when the skin was stripped by using adhesive 
tape, the uptake was significantly greater. The clinical relevance of this model to skin that 
has been shaved is difficult to extrapolate. A study in adults in which researchers used 
radiolabeled aluminum in an antiperspirant revealed absorption of only 0.012% of the 
tracer.26 This study involved using tape to strip the previously shaved underarm area for 
skin samples. This would indicate that the absorption of aluminum from antiperspirants, 
even with skin that has been shaved, is apparently minimal. Mixed epidemiological data 
from population studies reveal no association27 or a possible association28 of aluminum-
containing antiperspirants with breast cancer. Although there is no solid clinical evidence 
of toxicity, there are calls in the literature for reduction of the aluminum in 
antiperspirants.29 
 
VACCINE ADJUVANTS 
Aluminum is the predominant adjuvant used in human vaccines, although not all vaccines. 
The aluminum content of vaccines is limited by the Code of Federal Regulations to 1.25 
 
 
mg per dose.30 The regulations also stipulate that data are required to reveal that the 
amount of aluminum is safe and necessary to produce the intended effect. The Centers 
for Disease Control and Prevention has stated that the amount of aluminum exposure 
from following the recommended vaccine schedule is low and that the aluminum is not 
readily absorbed by the body.31 The Centers for Disease Control and Prevention cited a 
study in which researchers calculated the aluminum exposure from vaccines during 
infancy and found the total to be far below the minimal risk levels established by the 
Agency for Toxic Substances and Disease Registry.32 The aluminum-containing 
adjuvants are reported to have minimal adverse effects but are effective at improving the 
antibody response.33 There are reports of a chronic local granulomatous inflammation 
known as macrophagic myofasciitis in a small number of patients after receiving 
intramuscular vaccines containing aluminum.33,34 This condition allegedly results from 
a chronic inflammatory response to the residual adjuvant aluminum at the vaccination site 
that leads to a constellation of neurologic symptoms, including myalgia, arthralgia, chronic 
fatigue, weakness, and cognitive issues.34 The number of patients reported to have the 
neurologic symptoms is low compared with the number of vaccinated individuals. The 
World Health Organization Global Advisory Committee of Vaccine Safety has not found 
that the data support an association between aluminum adjuvants and chronic neurologic 
diseases.35 The aluminum content of vaccines has been blamed for autism spectrum 
disorders, but a large meta-analysis of cohort studies evaluating vaccination and the risk 
of autism revealed that in pooled data of 1 256 407 children, the odds ratio of developing 
autism after vaccination was 0.99, with a 95% confidence interval of 0.92 to 1.06.36 
The aluminum adjuvants in the human papillomavirus vaccine have also been suggested 
as causing primary ovary insufficiency. However, the relationship suggested is based on 
a total of 6 case reports, most occurring years after vaccination, with only 1 patient having 
ovarian failure within several months of vaccination.37 These cases reports come after 
more than 170 million doses of the human papillomavirus vaccine have been 
administered. The aluminum adjuvants in vaccines are also accused of potentially 
triggering an autoimmune process. The autoimmune syndrome induced by adjuvants was 
proposed in 2011.38 The proposed criteria for this syndrome are extremely vague and 
general. Two of the major criteria are exposure to an external stimulus (infection, vaccine, 
 
 
silicone, or adjuvant) before symptoms occur and appearance of a long list of general 
somatic complaints. A review of the available literature for the purported autoimmune 
syndrome induced by adjuvants revealed that the human cases were so dissimilar in 
proposed triggers and clinical conditions that there was no evidence for a relationship 
between adjuvants and autoimmune conditions.39 
ALUMINUM AND ALZHEIMER DISEASE 
A long-standing hypothesis has been that aluminum is involved in the etiology of 
Alzheimer disease. This theory is based on the assumption that a long-term accumulation 
of aluminum in the brain could produce symptoms like dialysis-associated 
encephalopathy. The aluminum-induced neurofibrillary degeneration in animal studies 
also was similar to the pathology observed in human patients with Alzheimer 
disease.40 A meta-analysis used to evaluate chronic aluminum-containing antacid use 
and the risk of Alzheimer disease revealed no association.41 In another meta-analysis, 
researchers examined dietary patterns of food consumption high in aluminum and the risk 
of dementia (70% of dementia is attributable to Alzheimer disease).42 This meta-analysis 
also included 1 study of aluminum in drinking water and 1 study of aluminum-containing 
dust inhalation. The meta-analysis revealed an increased relative risk of dementia of 2.24 
with increased aluminum exposure (P < .001).42 The largest meta-analysis of the 
association between aluminum and Alzheimer disease included a total of 8 studies and a 
total of 10 567 individuals.43 The follow-up time from the cited studies ranged from 8 to 
48 years, and the studies included drinking water (>100 µg/L aluminum concentration) 
and occupational exposures. Regarding the increased risk of Alzheimer disease, the 
authors of this meta-analysis reported a pooled odds ratio of 1.71, with a 95% confidence 
interval of 1.35 to 2.18.43 
 
SUMMARY OF KEY POINTS 
The 1996 American Academy of Pediatrics publication regarding aluminum toxicity was 
a policy statement. The primary concern in 1996 was renal dialysates, which has 
resolved. Currently, there are a variety of new issues concerning aluminum, the primary 
 
 
one being the aluminum concentration in parenteral nutrition components. However, there 
are no clinic alternatives for some of these components, and some of the other issues are 
still lacking the depth of data to support more definitive policy statements. Therefore, this 
updated document on aluminum toxicity was prepared as a technical review. A summary 
of the primary issues concerning aluminum is provided in the following points: 
1. The greatest risk of aluminum exposure occurs in intravenous preparations for 
micronutrient delivery in parenteral nutrition. Aluminum exposure via parenteral 
nutrition has been shown to have long-term effects in preterm infants. Every effort 
should be made to minimize the aluminum content, although with the currently 
available products, the concentration will still be above the recommended amount. 
2. Patients with renal disease should reduce aluminum exposure by avoiding 
aluminum-containing phosphate binders and other medications containing high 
amounts of aluminum to reduce aluminum exposure. 
3. Despite having aluminum concentrations higher than those in human milk, infant 
formulas have not been documented to result in any long-term health concerns. 
Studies are needed to assess the potential health risks attributable to the 
aluminum content in infant formulas, especially in potentially vulnerable 
populations. 
4. Antiperspirants have a high aluminum content, but there is not enough evidence 
to suggest long-term health concerns. 
5. Aluminum adjuvants are extremely safe and effective at producing an immune 
response with rare adverse effects. 
6. Meta-analyses have suggested an association between aluminum and Alzheimer 
disease with long-term high-concentration exposures. 
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